The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

@article{Sasaki2010TheNF,
  title={The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.},
  author={Takaaki Sasaki and Katsuhiro Okuda and Wei Zheng and James E. Butrynski and Marzia Capelletti and Liping Wang and Nathanael S Gray and Keith D. Wilner and James G. Christensen and George Daniel Demetri and Geoffrey I. Shapiro and Scott J Rodig and Michael J. Eck and Pasi Antero J{\"a}nne},
  journal={Cancer research},
  year={2010},
  volume={70 24},
  pages={10038-43}
}
The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be limited by acquired drug resistance. Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy. When present in cis with an ALK translocation, this… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS